Accelerator Mass Spectrometry in hADME – Recent and Future Advances

Recorded: July 2025

Accelerator Mass Spectrometry in human ADME is transforming the way hADME studies are conducted. This webinar, took place on July 30th at 8 am PT / 11 am ET / 4 pm GMT. Experts explored current AMS-enabled approaches, the qualification of low-energy AMS (Ionplus LEA), and the integration of CO₂-interfaced systems. Attendees will gain valuable insights into how these innovations are enhancing sensitivity, efficiency, and data quality in pharmacokinetic research, and what the future holds for AMS in drug development.

Agenda:

These key topics were explored:

• Modern approaches to human ADME studies, enabled by AMS and potential future advances 
  • Overview of current approaches to the execution of ADME, with AMS technology and potential future developments
• Qualification of low-energy accelerator mass spectrometry and potential benefits in ADME sample analysis 
  • Qualification of CO2-interfaced low-energy AMS and overview of its utility in ADME studies

Moderator by:

Marie Croft - Scientific Director, Radiolabelled Sciences at Pharmaron

Marie Croft is the Scientific Director, Radiolabelled Sciences at Pharmaron.  She has over 17 years of experience in bioanalytical applications of accelerator mass spectrometry (AMS).   

Following her graduation from De Montfort University in 2004, Marie began her career with Xceleron Ltd, gaining hands-on laboratory experience in AMS and LC-AMS analysis.  During this time, she conducted research into AMS microdosing, specifically cassette dosing in DDI studies, as well as the combined use of AMS and PET after microdose administration.  She received her PhD in ‘Applications of human microdosing with accelerator mass spectrometry’ from the University of York in 2013. Marie works primarily with the ¹⁴C-bioanalysis team based at Pharmaron ABS, Germantown, and plays a key role in the design, review, and execution of hADME studies. 

Speakers:

Graeme Young - Consultant at Accelerated Medical Solutions, Ltd.

Dr. Graeme Young was employed in the departments of Drug Metabolism and Translational Medicine at GSK for over 36 years. 

Graeme acted as a "champion" of Accelerator Mass Spectrometry (AMS) for many years, with responsibility for bringing the first AMS in-house to a pharmaceutical company and applying it to clinical and non-clinical projects at all stages of development. 

Graeme has been the lead author or contributing author to many groundbreaking papers published on the subject of AMS and its application to Drug Metabolism and Bioanalysis science, as well as broader clinical strategy papers. 

He was Chair of the Global Bioanalysis Consortium team on AMS, bringing together leaders in the field to help establish harmonized approaches to clinical study support using this enabling technology.  He led the EFPIA DMPK Network-sponsored human ADME paradigm shift working group (WG), which produced key white papers, including one on the paradigm shift in human ADME and approaches to providing IV PK in humans.  He was also an invited co-chair to the IQ WG on human mass balance studies.  Graeme continues to have broader interests in accelerating translational drug development through the application of novel strategies. 

Stephen English - Director, 14C Bioanalysis at Pharmaron 

Stephen English is the Director, 14C Bioanalysis at Pharmaron.